亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Omalizumab in the treatment of bullous pemphigoid resistant to first-line therapy: a French national multicentre retrospective study of 100 patients

奥马佐单抗 医学 皮肤病科 大疱性类天疱疮 回顾性队列研究 类天疱疮 免疫球蛋白E 儿科 内科学 免疫学 抗体
作者
Réda Chebani,F. Lombart,G. Chaby,A. Dadban,S. Debarbieux,M. Viguier,S. Oro,Anne Pham‐Ledard,C. Bédane,C. Picard‐Dahan,C. Berthin,O. Dereure,M.P. Konstantinou,Marion Castel,F. Jouen,P. Joly,V. Seta,S. Duvert‐Lehembre,Christelle Le Roux,G. Quéreux
出处
期刊:British Journal of Dermatology [Oxford University Press]
卷期号:190 (2): 258-265 被引量:36
标识
DOI:10.1093/bjd/ljad369
摘要

Abstract Background Interest in the use of omalizumab to treat bullous pemphigoid (BP) in the event of resistance or contraindication to conventional therapies is currently based on limited evidence. Objectives To assess the effectiveness and safety of omalizumab in BP and to identify predictive factors in response to treatment. Methods We conducted a French national multicentre retrospective study including patients with a confirmed diagnosis of BP treated with omalizumab after failure of one or several treatment lines. We excluded patients with clinically atypical BP, as per Vaillant’s criteria. The criteria for clinical response to omalizumab were defined according to the 2012 international consensus conference. Anti-BP180-NC16A IgE enzyme-linked immunosorbent assay was performed on sera collected before initiating omalizumab, when available. Results Between 2014 and 2021, 100 patients treated in 18 expert departments were included. Median age at diagnosis was 77 years (range 20–98). Complete remission (CR) was achieved in 77% of patients, and partial remission in an additional 9%. CR was maintained ‘off therapy’ in 11.7%, ‘on minimal therapy’ in 57.1%, and ‘on non-minimal therapy’ in 31.2%. Median time to CR was 3 months (range 2.2–24.5). Relapse rate was 14%, with a median follow-up time of 12 months (range 6–73). Adverse events occurred in four patients. CR was more frequently observed in patients with an increased serum baseline level of anti-BP180-NC16A IgE (75% vs. 41%; P = 0.011). Conversely, urticarial lesions, blood total IgE concentration or eosinophil count were not predictive of CR. Patients with an omalizumab dosage > 300 mg every 4 weeks showed a similar final outcome to those with a dosage ≤ 300 mg every 4 weeks, but control of disease activity [median 10 days (range 5–30) vs. 15 days (range 10–60); P < 0.001] and CR [median 2.4 months (range 2.2–8.2) vs. 3.9 months (range 2.3–24.5); P < 0.001] were achieved significantly faster. Conclusions We report the largest series to date of BP treated by omalizumab and confirm its effectiveness and safety in this indication. Serum baseline level of anti-BP180-NC16A IgE may predict response to treatment.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
研友_VZG7GZ的应助被佳莉采纳,获得10
1秒前
c_phoebe完成签到,获得积分10
8秒前
14秒前
16秒前
32秒前
懵懂的念波完成签到,获得积分10
32秒前
34秒前
痴情的归尘完成签到,获得积分10
34秒前
35秒前
40秒前
桐桐的应助被南宫雪采纳,获得10
43秒前
zzz完成签到,获得积分10
46秒前
科目三的应助被科研通管家采纳,获得10
51秒前
51秒前
充电宝的应助被科研通管家采纳,获得10
51秒前
null的应助被科研通管家采纳,获得10
51秒前
Orange的应助被科研通管家采纳,获得10
52秒前
英俊的铭的应助被科研通管家采纳,获得10
52秒前
55秒前
忧郁思远完成签到,获得积分10
56秒前
59秒前
teyr完成签到,获得积分10
1分钟前
机灵的夜梅完成签到,获得积分10
1分钟前
Pikachu完成签到,获得积分10
1分钟前
1分钟前
高大的紫萍完成签到,获得积分10
1分钟前
小祝没吃饱完成签到,获得积分10
1分钟前
1分钟前
1分钟前
天真的音完成签到,获得积分10
1分钟前
陳源完成签到 ,获得积分10
1分钟前
ABC完成签到,获得积分10
1分钟前
芋头完成签到,获得积分10
2分钟前
2分钟前
复杂鸵鸟完成签到,获得积分10
2分钟前
2分钟前
Younger发布了新的文献求助10
2分钟前
2分钟前
忧郁依柔完成签到,获得积分10
2分钟前
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8158694
求助须知:如何正确求助?哪些是违规求助? 9554462
关于积分的说明 21719198
捐赠科研通 7748257
什么是DOI,文献DOI怎么找? 3427070
关于科研通互助平台的介绍 2551949
邀请新用户注册赠送积分活动 2471308